The U.S. Food and Drug Administration has delayed action for the promising Alzheimer’s treatment donanemab, the drug manufacturer said on Friday. Eli Lilly said the FDA would wait on ruling ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 earnings figures before ...

The product’s manufacturer, Eli Lilly, and the NHS have been asked to furnish more information to address “areas of uncertainty” in the currently available evidence. Donanemab works by ...

Eli Lilly's innovative culture and strong financial ... Lilly is developing a new Alzheimer’s drug (Kisunla/donanemab) that could become a major blockbuster, especially since few treatment ...

Nico Chen’s rating is based on a combination of factors that highlight Eli Lilly & Co’s promising ... for diabetes and weight loss, and Donanemab for Alzheimer’s disease.

Eli Lilly & Co. LLY is a major global pharmaceutical ... FDA-approved and launched treatment for Alzheimer's disease, Donanemab, sold as Kisunla. Mirikizumab is a treatment for Crohn's disease ...

We maintain Eli Lilly’s High Uncertainty Rating ... including level of insurance coverage and pricing. Alzheimer’s drug donanemab holds the potential to become another major new drug, but ...